Barloworld Limited, the industrial processing, distribution, and services company focused on Industrial Equipment and Services and Consumer Industries (Ingrain), has reported a substantial decline in financial performance for the year ended 30 September 2025. Although characterised as "interim results" in the request, the detailed figures reflect the company's full annual performance for the 2025 fiscal year.The Bad: Declining revenue and profitabilityThe most significant negative trends for the year were e ...

Group 1 - The core point of the article is that Jia Rong Technology is planning to acquire control of Hangzhou Lanran Technology through a share issuance agreement, which is expected to enhance its membrane technology business [1] - Jia Rong Technology signed a share issuance agreement with major shareholders of Hangzhou Lanran on November 16, 2025, to purchase all shares held by these shareholders [1] - The company is expected to disclose the transaction plan within 10 trading days, with a deadline for resuming trading by December 1, 2025, if the plan is not disclosed [1] Group 2 - Hangzhou Lanran's product line is complementary to Jia Rong Technology's membrane technology, focusing on ion exchange membranes and related equipment [1] - Hangzhou Lanran has a subsidiary, Quzhou Lanran New Materials, which has established a production line with an annual capacity of 850,000 square meters for ion exchange membranes [1] - Jia Rong Technology's main business includes special membrane separation materials and high-concentration wastewater treatment services, with a market presence in areas such as landfill leachate and industrial wastewater [2] Group 3 - In 2022, Hangzhou Lanran faced issues with revenue recognition during its IPO attempt, leading to the withdrawal of its application in December 2022 [2] - The company was highlighted as a typical regulatory case by the Shenzhen Stock Exchange in April 2023 [2] - For the first three quarters of 2025, Jia Rong Technology reported a revenue of 362 million yuan, a year-on-year decrease of 7.53%, while its net profit attributable to shareholders increased by 12.95% to 59.3 million yuan [2]

Core Viewpoint - Gushengtang Singapore, a subsidiary of Gushengtang, is acquiring 100% equity of DA ZHONG TANG PTE.LTD. to expand its offline medical network and increase market share in Singapore, aiming for synergies with existing operations [1] Group 1 - The acquisition price is determined through fair negotiations and will be funded by net proceeds from placements, idle funds of the group, and Gushengtang Singapore's own funds [1] - After the acquisition, DA ZHONG TANG will become a subsidiary of Gushengtang, and its financial performance will be included in the group's consolidated financial statements [1]

Core Points - Cidara Therapeutics (CDTX.US) shares surged over 105% to a new eight-year high of $217.8 following the announcement of a definitive agreement for acquisition by Merck (MRK.US) at $221.50 per share in cash [1] - The total value of the transaction is approximately $9.2 billion, and it has been approved by the boards of both companies [1] - The acquisition is subject to the approval of the Hart-Scott-Rodino Antitrust Improvements Act (HSR) and other customary closing conditions, with an expected completion in the first quarter of 2026 [1] - Merck's research laboratories president, Dr. D. Lee, stated that this acquisition expands and enhances their respiratory product portfolio and R&D pipeline [1]

Core Points - Cidara Therapeutics (CDTX.US) shares surged over 105% to a new eight-year high of $217.8 following the announcement of a definitive agreement for acquisition by Merck (MRK.US) at $221.50 per share in cash [1] - The total value of the transaction is approximately $9.2 billion, and it has been approved by the boards of both companies [1] - The acquisition is subject to the approval of the Hart-Scott-Rodino Antitrust Improvements Act (HSR) and other customary closing conditions, with an expected completion in Q1 2026 [1] - Merck's President of Research Laboratories, Dr. Dean Li, stated that this acquisition enhances and expands their respiratory product portfolio and R&D pipeline [1]

（文章来源：证券日报） 证券日报网讯甬矽电子11月14日在互动平台回答投资者提问时表示，公司本次通过公开竞拍的方式获取 宁波宇昌的100%股权，全程公开透明，资金来源为公司自有及自筹资金，不涉及可转债募集资金，价 格基于第三方评估机构出具的评估结果确定，具体情况详见公司《关于控股子公司参与竞拍宁波宇昌建 设发展有限公司股权的公告》。本次收购的标的公司核心资产为公司正在使用的二期厂房，也是公司总 规划投资111亿元二期项目所在地。公司二期厂房采用"EPC+F"代建模式，前期由公司租赁使用，根据 企业会计准则的相关要求，公司已将与二期厂房相关的租赁及潜在的回购义务确认为使用权资产与租赁 负债。因此本次收购不会使得公司负债总额和财务费用产生重大变化，不会对生产经营产生重大不利影 响；同时，本次收购完成后，可以实现对主要资产的自主控制，有利于稳定经营环境、降低未来不确定 性，符合公司战略。本次收购不会导致公司主营业务发生重大变化，公司亦不会开展房地产、工程建设 等业务。 ...

11月12日，港股耀才证券股价开盘后快速下冲，最大跌幅超过13%。随后交易时间段，公司股价开始抬 升，于收盘后录得跌幅5.28%。 耀才证券的这场股价震荡与蚂蚁集团的收购案相关。据悉，按照双方原定收购协议，交易截止日期是 2025年的11月25日，但协议的剩余完成条件可能于最终截止日期或之前未能达成，要约人正考虑可能延 长最终截止日期。 收购案起"波折" 蚂蚁集团对于耀才证券的收购案进展并没有预期的顺利。 早在4月25日，耀才证券就发布公告称，上海云进通过旗下子公司蚂蚁财富，以每股3.28港元的价格向 耀才证券发起要约收购，交易股份约为8.58亿股，占已发行股份总数的约50.55%，价格合计28.14亿港 元。倘若上述交易成功，耀才证券将成功易主，投入蚂蚁集团麾下。 10月10日晚间，上述收购案进一步推进。耀才证券发布公告称，蚂蚁集团收购耀才证券的事项已经获香 港证监会批准。目前，还需国家发展改革委审批后落定。 彼时，港股耀才证券金融（HK.01428）曾因此消息实现了一波34.52%的大幅上涨。 11月11日晚，上述收购案出现波折。耀才证券发布消息称，收购要约人蚂蚁集团方面正考虑可能延长交 易的最后截止日期 ...

Core Viewpoint - Shunlong Holdings is transferring shares worth HKD 295 million, representing 50.68% of its stock, from Emperor Securities Hong Kong to Bank of Communications International Securities [1] Group 1: Share Transfer - On November 13, Shunlong Holdings' shareholders transferred shares valued at HKD 295 million, which accounts for 50.68% of the company's stock [1] Group 2: Acquisition Announcement - Shunlong Holdings announced plans to acquire Hio Pro (Vietnam) Sporting Goods Company Limited for USD 2.5 million, which represents the entire paid-up charter capital of VND 615.20 billion [1] - The target company is a wholly foreign-owned enterprise in Vietnam, primarily engaged in the manufacturing of golf equipment and related components [1] Group 3: Strategic Rationale - The acquisition allows Shunlong Holdings to manufacture golf products in Vietnam, where export tariffs are lower than those from China, thereby alleviating tariff burdens and enhancing competitiveness in the U.S. market [1] - This strategic move aims to improve the overall operational efficiency of the group while maintaining competitiveness in the golf business [1]

Core Viewpoint - The stock price of Yao Cai Securities experienced significant volatility due to the acquisition proposal from Ant Group, with a maximum drop of over 13% before closing down 5.28% [2]. Group 1: Acquisition Details - Ant Group initiated a takeover bid for Yao Cai Securities on April 25, offering HKD 3.28 per share for approximately 858 million shares, totaling HKD 28.14 billion, which represents about 50.55% of the total issued shares [3]. - The acquisition has received approval from the Hong Kong Securities and Futures Commission, but it still requires approval from the National Development and Reform Commission [3]. - On November 11, Yao Cai Securities announced that Ant Group is considering extending the final deadline for the acquisition [5]. Group 2: Financial Performance - Yao Cai Securities reported total revenues of HKD 10.14 billion, HKD 10.50 billion, and HKD 11.21 billion for the fiscal years 2022 to 2024, with year-on-year changes of -19.96%, -4.05%, and 3.09% respectively [8]. - The net profit attributable to the parent company for the same period was HKD 4.55 billion, HKD 5.43 billion, and HKD 5.06 billion, with year-on-year changes of -20.23%, 10.53%, and -9.95% respectively [8]. Group 3: Company Background - Yao Cai Securities was founded in 1995 by Ye Maolin and offers services including Hong Kong stock trading, margin financing, securities custody, futures and options trading, leveraged forex trading, and spot gold and silver trading [8]. - The company is known for its low commission rates, having significantly reduced its commission from 0.25% to 0.05% after the government abolished the minimum commission system in 2003 [8].

11月12日，港股耀才证券股价开盘后快速下冲，最大跌幅超过13%。随后交易时间段，公司股价开始抬 升，于收盘后录得跌幅5.28%。 耀才证券的这场股价震荡与蚂蚁集团的收购案相关。据悉，按照双方原定收购协议，交易截止日期是 2025年的11月25日，但协议的剩余完成条件可能于最终截止日期或之前未能达成，要约人正考虑可能延 长最终截止日期。 收购案起"波折" 蚂蚁集团对于耀才证券的收购案进展并没有预期的顺利。 早在4月25日，耀才证券就发布公告称，上海云进通过旗下子公司蚂蚁财富，以每股3.28港元的价格向 耀才证券发起要约收购，交易股份约为8.58亿股，占已发行股份总数的约50.55%，价格合计28.14亿港 元。倘若上述交易成功，耀才证券将成功易主，投入蚂蚁集团麾下。 10月10日晚间，上述收购案进一步推进。耀才证券发布公告称，蚂蚁集团收购耀才证券的事项已经获香 港证监会批准。目前，还需国家发展改革委审批后落定。 就蚂蚁集团延长最终截止日期可能带来的影响，南都湾财社向耀才证券发送了采访函，但并未收到回 复。 耀才+蚂蚁背后有何影响？ 彼时，港股耀才证券金融（HK.01428）曾因此消息实现了一波34.52%的大 ...